Obagi Expands Into Injectables With Filler Line Headed to U.S.

Obagi Expands Into Injectables With Filler Line Headed to U.S.

Discover how Obagi is entering the injectables space after acquiring U.S. rights to the Saypha filler line, developed in Europe and pending FDA approval.

#Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha, Under the Obagi Medical Brand ?? A Strategic Shift Amid Leadership Changes,

Waldencast's Strategic Acquisition: Strengthening Obagi Medical's Injectable Portfolio Amidst Leadership Changes In a pivotal moment for both Waldencast and the evolving skincare landscape, the acquisition of Novaestiq Corp. and the U.S. rights to their popular injectable hyaluronic acid gel line, Saypha, is positioning Obagi Medical as a formidable player in the aesthetic market. This acquisition comes on the heels of a leadership shake-up with…

Waldencast Expands Obagi Into Dermal Fillers With Novaestiq Corp. Acquisition

Waldencast, owner of Obagi Medical and Milk Makeup, is taking a major step into medical aesthetics by acquiring Novaestiq Corp. and doubling the size of its addressable market in the process. The deal gives Waldencast the perpetual, exclusive rights in the United States to Saypha, a hyaluronic ... The post Waldencast Expands Obagi Into Dermal Fillers With Novaestiq Corp. Acquisition appeared first on Beauty Independent.